LivaNova (LIVN) to Announce Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is expected to be posting its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $1.09 per share and revenue of $380.5370 million for the quarter. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm’s revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.88 earnings per share. On average, analysts expect LivaNova to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

LivaNova Stock Performance

NASDAQ LIVN opened at $80.14 on Monday. The stock has a 50-day simple moving average of $79.09 and a two-hundred day simple moving average of $70.19. The firm has a market capitalization of $4.40 billion, a P/E ratio of 41.10 and a beta of 0.86. LivaNova has a fifty-two week low of $41.01 and a fifty-two week high of $85.27. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Freedom Capital raised LivaNova to a “hold” rating in a report on Tuesday, June 30th. Mizuho upped their price objective on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Barclays raised their price objective on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Finally, Zacks Research raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $81.38.

Insiders Place Their Bets

In related news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. State of Wyoming acquired a new position in shares of LivaNova during the 2nd quarter worth approximately $31,000. Quarry LP acquired a new stake in shares of LivaNova in the third quarter valued at approximately $36,000. EverSource Wealth Advisors LLC increased its holdings in shares of LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the last quarter. UMB Bank n.a. lifted its position in LivaNova by 22.6% during the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock worth $60,000 after buying an additional 179 shares in the last quarter. Finally, Johnson Financial Group Inc. purchased a new position in LivaNova during the third quarter worth approximately $63,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.